STRONCIJ RANELAT – NOVA PARADIGMA ZA LIJEČENJE POSTMENOPAUZALNE OSTEOPOROZE

Mirko Koršić, Zlatko Giljević, Darko Kaštelan

Osteoporoza je postala globalni javnozdravstveni problem, jer je svjetska populacija sve starija. U zadnjih desetak godina svjedoci smo velikog napretka u liječenju postmenopauzalne osteoporoze. Najčešće su propisivani antiresorptivni lijekovi. U zadnjih nekoliko godina kliničku primjenu našao je i osteoanabolički lijek teriparatid, a nedavno se pojavio stroncij ranelat, lijek s osteoanaboličkim i antiresorptivnim djelovanjem na progresiju kosti. Klinička istaživanja (faza III) potvrdila su djelotvornost stroncij ranelata u liječenju postmenpauzalne osteoporoze. Stroncij ranlat je lijek koji karakterizira nova paradigma mehanizma djelovanja i koji zaslužuje mjesto među prokušanim lijekovima za liječenje postmenopauzalne osteoporoze.

Summary. Osteoporosis has become a global public health issue due to the fact that the world population has gotten older. In the past ten years we have witnessed a great improvement in the treatment of postmenopausal osteoporosis. The anti- resorptive drugs are the most presribed ones. In the last couple of years osteoanabolic drug, a teriparatid, was introduced into the clinical use, and recently a strontium ranelate has occured as a drug with osteoanabolic and antiresorptive effect in bone formation. Clinical trials (phase III) have proved the efficiency of strontium ranelate in postmenopausal osteoporosis treat- ment. Strontium ranelate is a drug characterized by the new paradigm of action mechanism on bone, which has its place among the already well-proven drugs in postmenopausal osteoporosis treatment.